Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression

Kyla Walworth, Manish Bodas, Ryan John Campbell, Doug Swanson, Ajit Sharma, Neeraj Vij

Research output: Contribution to journalArticle

Abstract

Elevated valosin containing protein (VCP/p97) levels promote the progression of non-small cell lung carcinoma (NSCLC). Although many VCP inhibitors are available, most of these therapeutic compounds have low specificity for targeted tumor cell delivery. Hence, the primary aim of this study was to evaluate the in vitro efficacy of dendrimer-encapsulated potent VCP-inhibitor drug in controlling non-small cell lung carcinoma (NSCLC) progression. The VCP inhibitor(s) (either in their pure form or encapsulated in generation-4 PAMAM-dendrimer with hydroxyl surface) were tested for their in vitro efficacy in modulating H1299 (NSCLC cells) proliferation, migration, invasion, apoptosis and cell cycle progression. Our results show that VCP inhibition by DBeQ was significantly more potent than NMS-873 as evident by decreased cell proliferation (pDBeQ) treatment increased ubiquitinated-protein accumulation in soluble protein-fraction (immunoblotting) of H1299 cells as compared to DDN-control, implying the effectiveness of DBeQ in proteostasis-inhibition. We verified by immunostaining that DDNDBeQ treatment increases accumulation of ubiquitinated-proteins that co-localizes with an ER-marker, KDEL. We observed that proteostasis-inhibition with DDNDBeQ, significantly decreased cell migration rate (scratch-assay and transwell-invasion) as compared to the control-DDN treatment (pDBeQ treatment showed a significant decrease in cell proliferation (pDBeQ treatment as compared to control-DDN. Moreover, we confirmed by clonogenic-assay that DDNDBeQ treatment significantly (p

Original languageEnglish (US)
Article numbere0158507
JournalPLoS One
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Dendrimers
Non-Small Cell Lung Carcinoma
carcinoma
Cell proliferation
lungs
Cells
Ubiquitinated Proteins
cell proliferation
Growth
Assays
proteins
cells
Cell Proliferation
assays
Therapeutics
Cell Movement
immunoblotting
cell movement
Hydroxyl Radical
Tumors

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Walworth, K., Bodas, M., Campbell, R. J., Swanson, D., Sharma, A., & Vij, N. (2016). Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression. PLoS One, 11(7), [e0158507]. https://doi.org/10.1371/journal.pone.0158507

Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression. / Walworth, Kyla; Bodas, Manish; Campbell, Ryan John; Swanson, Doug; Sharma, Ajit; Vij, Neeraj.

In: PLoS One, Vol. 11, No. 7, e0158507, 01.07.2016.

Research output: Contribution to journalArticle

Walworth, K, Bodas, M, Campbell, RJ, Swanson, D, Sharma, A & Vij, N 2016, 'Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression', PLoS One, vol. 11, no. 7, e0158507. https://doi.org/10.1371/journal.pone.0158507
Walworth, Kyla ; Bodas, Manish ; Campbell, Ryan John ; Swanson, Doug ; Sharma, Ajit ; Vij, Neeraj. / Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression. In: PLoS One. 2016 ; Vol. 11, No. 7.
@article{778f42dbaef54d9bb08dafd1f30facd2,
title = "Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression",
abstract = "Elevated valosin containing protein (VCP/p97) levels promote the progression of non-small cell lung carcinoma (NSCLC). Although many VCP inhibitors are available, most of these therapeutic compounds have low specificity for targeted tumor cell delivery. Hence, the primary aim of this study was to evaluate the in vitro efficacy of dendrimer-encapsulated potent VCP-inhibitor drug in controlling non-small cell lung carcinoma (NSCLC) progression. The VCP inhibitor(s) (either in their pure form or encapsulated in generation-4 PAMAM-dendrimer with hydroxyl surface) were tested for their in vitro efficacy in modulating H1299 (NSCLC cells) proliferation, migration, invasion, apoptosis and cell cycle progression. Our results show that VCP inhibition by DBeQ was significantly more potent than NMS-873 as evident by decreased cell proliferation (pDBeQ) treatment increased ubiquitinated-protein accumulation in soluble protein-fraction (immunoblotting) of H1299 cells as compared to DDN-control, implying the effectiveness of DBeQ in proteostasis-inhibition. We verified by immunostaining that DDNDBeQ treatment increases accumulation of ubiquitinated-proteins that co-localizes with an ER-marker, KDEL. We observed that proteostasis-inhibition with DDNDBeQ, significantly decreased cell migration rate (scratch-assay and transwell-invasion) as compared to the control-DDN treatment (pDBeQ treatment showed a significant decrease in cell proliferation (pDBeQ treatment as compared to control-DDN. Moreover, we confirmed by clonogenic-assay that DDNDBeQ treatment significantly (p",
author = "Kyla Walworth and Manish Bodas and Campbell, {Ryan John} and Doug Swanson and Ajit Sharma and Neeraj Vij",
year = "2016",
month = "7",
day = "1",
doi = "10.1371/journal.pone.0158507",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Dendrimer-based selective proteostasis-inhibition strategy to control NSCLC growth and progression

AU - Walworth, Kyla

AU - Bodas, Manish

AU - Campbell, Ryan John

AU - Swanson, Doug

AU - Sharma, Ajit

AU - Vij, Neeraj

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Elevated valosin containing protein (VCP/p97) levels promote the progression of non-small cell lung carcinoma (NSCLC). Although many VCP inhibitors are available, most of these therapeutic compounds have low specificity for targeted tumor cell delivery. Hence, the primary aim of this study was to evaluate the in vitro efficacy of dendrimer-encapsulated potent VCP-inhibitor drug in controlling non-small cell lung carcinoma (NSCLC) progression. The VCP inhibitor(s) (either in their pure form or encapsulated in generation-4 PAMAM-dendrimer with hydroxyl surface) were tested for their in vitro efficacy in modulating H1299 (NSCLC cells) proliferation, migration, invasion, apoptosis and cell cycle progression. Our results show that VCP inhibition by DBeQ was significantly more potent than NMS-873 as evident by decreased cell proliferation (pDBeQ) treatment increased ubiquitinated-protein accumulation in soluble protein-fraction (immunoblotting) of H1299 cells as compared to DDN-control, implying the effectiveness of DBeQ in proteostasis-inhibition. We verified by immunostaining that DDNDBeQ treatment increases accumulation of ubiquitinated-proteins that co-localizes with an ER-marker, KDEL. We observed that proteostasis-inhibition with DDNDBeQ, significantly decreased cell migration rate (scratch-assay and transwell-invasion) as compared to the control-DDN treatment (pDBeQ treatment showed a significant decrease in cell proliferation (pDBeQ treatment as compared to control-DDN. Moreover, we confirmed by clonogenic-assay that DDNDBeQ treatment significantly (p

AB - Elevated valosin containing protein (VCP/p97) levels promote the progression of non-small cell lung carcinoma (NSCLC). Although many VCP inhibitors are available, most of these therapeutic compounds have low specificity for targeted tumor cell delivery. Hence, the primary aim of this study was to evaluate the in vitro efficacy of dendrimer-encapsulated potent VCP-inhibitor drug in controlling non-small cell lung carcinoma (NSCLC) progression. The VCP inhibitor(s) (either in their pure form or encapsulated in generation-4 PAMAM-dendrimer with hydroxyl surface) were tested for their in vitro efficacy in modulating H1299 (NSCLC cells) proliferation, migration, invasion, apoptosis and cell cycle progression. Our results show that VCP inhibition by DBeQ was significantly more potent than NMS-873 as evident by decreased cell proliferation (pDBeQ) treatment increased ubiquitinated-protein accumulation in soluble protein-fraction (immunoblotting) of H1299 cells as compared to DDN-control, implying the effectiveness of DBeQ in proteostasis-inhibition. We verified by immunostaining that DDNDBeQ treatment increases accumulation of ubiquitinated-proteins that co-localizes with an ER-marker, KDEL. We observed that proteostasis-inhibition with DDNDBeQ, significantly decreased cell migration rate (scratch-assay and transwell-invasion) as compared to the control-DDN treatment (pDBeQ treatment showed a significant decrease in cell proliferation (pDBeQ treatment as compared to control-DDN. Moreover, we confirmed by clonogenic-assay that DDNDBeQ treatment significantly (p

UR - http://www.scopus.com/inward/record.url?scp=84979496979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979496979&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0158507

DO - 10.1371/journal.pone.0158507

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0158507

ER -